Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Sana Biotechnology

Main focus: Cellular engineering for genetic diseases and cancer

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-Cas12b

Funding stage: Public (NASDAQ:SANA)

Location: Seattle, Washington, United States



Partners: Beam Therapeutics

Sana Biotechnology is a Seattle-based company that focuses on the development of in vivo and ex vivo engineered cell therapies. Using its Fusogen technology platform, the company aims to create in vivo engineered CAR-T cells, which might circumvent many of the obstacles associated with conventional CAR-T cell therapies. Likewise, the company's Hypoimmune technology is being applied for the development of ex vivo engineered donor- and stem cell-derived cellular therapies. The company has obtained licenses from Beam Therapeutics to use the CRISPR-Cas12b system as part of a number of its ex vivo engineered cell programmes.


HashtagSana Biotechnology

Company: Sana Biotechnology
Search CRISPR Medicine